| __timestamp | Soleno Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 59644696 |
| Thursday, January 1, 2015 | 7878291 | 79541000 |
| Friday, January 1, 2016 | 8366794 | 98015000 |
| Sunday, January 1, 2017 | 6610381 | 103958000 |
| Monday, January 1, 2018 | 6556000 | 103654000 |
| Tuesday, January 1, 2019 | 6930000 | 128951000 |
| Wednesday, January 1, 2020 | 8758000 | 135799000 |
| Friday, January 1, 2021 | 10806000 | 149883000 |
| Saturday, January 1, 2022 | 9844000 | 220206000 |
| Sunday, January 1, 2023 | 13481000 | 265542000 |
Cracking the code
In the competitive landscape of biotechnology, understanding operational efficiency is crucial. Soleno Therapeutics, Inc. and Travere Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Soleno's Selling, General, and Administrative (SG&A) expenses grew modestly, peaking at approximately $13.5 million in 2023. In contrast, Travere's SG&A expenses surged, reaching around $265.5 million in the same year. This represents a staggering increase of over 340% from their 2014 figures.
While Soleno maintained a steady growth trajectory, Travere's aggressive expansion strategy is evident in their rising SG&A costs. This divergence highlights differing strategic priorities: Soleno's focus on controlled growth versus Travere's investment in scaling operations. Investors and industry analysts should consider these trends when evaluating the companies' long-term sustainability and market positioning.
Novo Nordisk A/S and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Johnson & Johnson vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
BioMarin Pharmaceutical Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Perrigo Company plc vs Soleno Therapeutics, Inc. Trends and Insights
ImmunityBio, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: Soleno Therapeutics, Inc. vs Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Xencor, Inc.
Who Optimizes SG&A Costs Better? Travere Therapeutics, Inc. or Novavax, Inc.